CR was 1(4.8%), PR 8(38.1%), SD 9(42.9%), PD 3(14.3%). The total response rate (CR+PR) was 42.9% (9/21).

• 21例晚期乳腺癌(均为复治病例)；完全缓解(CR)1例；占4.；8%25；部分缓解(PR)8例；占38